Harmony Biosciences Holdings (HRMY) is in the spotlight after announcing that its Phase 3 RECONNECT study for ZYN002 in Fragile X syndrome did not meet its main goal, citing higher than expected ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...

The Human Genome Project, launched in 1990 and completed in 2003, also moved the needle. Scientists had successfully ...

Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company.

Harmony Biosciences said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down more than 8%.

In a recent strategic move, Servier agreed to acquire Kaerus Bioscience’s potential Fragile X syndrome (FXS) treatment, KER-0193. "EC approves Servier’s Voranigo to treat IDH-mutant glioma " was ...

Sept 24 (Reuters) - Harmony Biosciences (HRMY.O), opens new tab said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its ...

Hyderabad: In the rapidly evolving world of reproductive medicine, ovarian tissue freezing is emerging as a groundbreaking advancement that offers new hope for women facing fertility ...

ACADIA Pharmaceuticals Inc. remains solid with Nuplazid and Daybue cash flows and valuation. Click here to read why ACAD ...

From diagnosis to the brutal treatment process, here's what veterinary professionals wish every dog owner understood about heartworm infection.

Invex Therapeutics Ltd. ( ($AU:IXC) ) just unveiled an update. Invex Therapeutics Ltd provided an operational update for the quarter ending ...